Inhibrx Biosciences, Inc. (INBX)

NMS – Цена в реальном времени. Валюта: USD

108.65

-18.93 (-14.84%)

При закрытии: May 12, 2026, 4:00 PM EDT

108.00

-0.65 (-0.60%)

До открытия: May 13, 2026, 8:48 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Inhibrx Biosciences, Inc. (INBX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Inhibrx Biosciences, Inc. (INBX)

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Видео

No Data

Пресс-релизы

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Inhibrx Announces Participation in Upcoming Scientific Conference

Search stocks

Inhibrx Biosciences, Inc. (INBX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Inhibrx Biosciences, Inc. (INBX)

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Видео

No Data

Пресс-релизы

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Inhibrx Announces Participation in Upcoming Scientific Conference